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Abstract  
 
Introduction: Locoregional recurrence (LRR) and distant recurrence after mastectomy 
are very important clinical endpoints.  It is well established that postmastectomy radiation 
therapy (PMRT) plays an important role in the treatment of locally advanced breast 
cancer and in the prevention of locoregional and distant recurrence.  There are also other 
prognostic factors such as nodal status, tumor size, and predictive factors such as 
hormone receptor status that are known to influence local and distant recurrence. 
There are varying reports on the rates of LRR after mastectomy. This variation in 
published rates of LRR creates a limitation in adequately assessing risk and benefits of 
PMRT to reduce local and distant recurrence.  Given the availability of more effective 
chemotherapy/systemic regimens, safer methods of delivering PMRT, there is a need to 
further evaluate the actual rates of locoregional and systemic recurrence after 
mastectomy.  
 
Aim: Our study sought to evaluate the local and distant recurrence rates in our population 
of patients who underwent mastectomy for breast cancer as well as the effects of various 
predictive and prognostic factors on local and distant recurrence. We hypothesized that 
the rate of local and distant recurrence in our patient population will be much lower than 
that stated in the published large-scale trials.  
 
Methods: All cases of breast cancer treated with mastectomy with or without post 
mastectomy radiation between Jan 1, 2000 and December 31, 2004, at Yale New Haven 
Hospital were analyzed.  
 
Results: A total of 443 cases were analyzed. Of the 356 cases in which local and distant 
recurrence status were known, 65 were non-invasive breast cancers while 291 were 
invasive breast cancer and invasiveness was unknown in 2 cases. Patients were followed 
for a mean of 79.6 months (std: 29.9). Local recurrence occurred in 2(3%) of non-
invasive cancers and 5(1.7%) of invasive cancers. Distant recurrence occurred in none of 
the non-invasive cancers and 32(11%) of the invasive cancers. There were significant 
differences in distant recurrence by T stage (p=0.016), N stage (p=0.022), ER status ( 
p<0.001) , PR status( p<0.001), molecular type ( p<0.001) and PMRT (p=0.01). However 
on multivariate analysis, only differences in nodal status (p=0.02) and ER status( 
p<0.001) remained significant for distant recurrence. 
 
 
Conclusion:  Our study found lower than expected rates of local and distant recurrence.  
 
Principal investigator: Dr Meena Moran 
Manual data collection from electronic medical records: Oluwatosin Onibokun 
Data Analysis and interpretation: Dr Donald Lannin and Oluwatosin Onibokun 
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Introduction  
Local and distant recurrence after mastectomy are very important clinical endpoints given 
their impact on morbidity, overall survival, as well as their devastating psychological 
effect.   However, the reported rates of locoregional recurrence (LRR) after mastectomy 
range from as low as 4% to as high as 32% (Katz et al., 2000; Overgaard et al., 1997; 
Ragaz et al., 2005). This variation in published rates of LRR creates a limitation in 
adequately assessing risk benefit ratios in clinical decision-making regarding the use of 
prophylaxis for LRR.  
There are factors such as postmastectomy radiation therapy (PMRT), hormone receptor 
status, nodal status and margin status that are known to influence local and distant 
recurrence. Of note, The American Society of Clinical Oncology (ASCO) recommends 
PMRT for patients with four or more positive axillary lymph nodes and those with stage 
III tumors (Recht et al., 2001). However, there is no standard recommendation on the use 
of PMRT in lower risk groups such as patients with fewer lymph nodes involved (one to 
three positive axillary lymph nodes) or in those without any lymph node involvement 
(Recht et al., 2001).  
Benefits of PMRT in the prevention of locoregional and distant recurrence were  
publicized by large randomized controlled studies in the late 1990’s and mid 2000 by two 
separate groups, the Danish and the British Columbians in Canada (Overgaard et al., 
1997; Overgaard et al., 1999; Ragaz et al., 2005). These studies showed the benefits of 
PMRT in reducing rates of locoregional recurrence and improving overall survival. 
However, the studies are criticized for inadequate information on lymph node 
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involvement and thus limited staging information, as well as for the use of chemotherapy 
regimens that are not considered standard of care in this present time.  
Specifically, one of the studies conducted by the Danish group (82b trial) that analyzed 
the effect of post mastectomy radiation, was conducted among 1708 high-risk 
premenopausal women who had all undergone mastectomy and chemotherapy with 
cyclophosphamide, methotrexate and fluorouracil (CMF). The result showed that at 10 
years, there was a lower locoregional recurrence rate of 9% in patients who received 
PMRT to the chest wall and regional lymphatics versus a higher rate of 32% in patients 
who did not receive PMRT (P< 0.001). The study also found superior disease free 
survival  (48% vs 34%, P < 0.001) and superior overall survival (54% vs 45%, P < 0.001) 
in patients who received PMRT versus patients who did not receive PMRT respectively.  
In the British Columbia study, they examined 318 high risk pre-menopausal women with 
breast cancer who either received adjuvant chemotherapy (CMF) and PMRT or 
underwent adjuvant chemotherapy (CMF) alone after mastectomy.  Their study showed 
similar results to the Danish trial with a 20 year survival free of isolated LRR of 90% in 
patients who received chemotherapy and radiation versus 74% in the group that got 
chemotherapy alone (P=0.002). However, the British Columbia study did not show a 
statistically significant difference in the overall survival of the group that received PMRT 
(RR 0.74, 95% CI= 0.53 to 1.02; P= 0.07).  Similarly, in trials done among 1460 post- 
menopausal women (Danish 82 c trial), a lower LRR of 8% was seen in high -risk 
women who received PMRT and tamoxifen versus a rate of 35% in patients who received 
tamoxifen alone without PMRT.  
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However, the high LRR rates in patients who did not receive PMRT published in these 
studies have been questioned given lower rates found in subsequent smaller studies 
among similar patient groups (Floyd et al., 2006; S. M. Macdonald et al., 2009; Panoff et 
al., 2011).   PMRT is not without its disadvantages with potential long-term risks 
including lymphedema, brachial plexus damage, radiation pneumonitis, cardiac toxicity, 
and radiation-induced second cancers (Feigenberg, Price Mendenhall, Benda, & Morris, 
2003; Ragaz et al., 2005; Recht et al., 2001). Therefore, the lower locoregional 
recurrence rates seen in more recent retrospective studies in women who did not undergo 
PMRT suggests a lower benefit for additional PMRT.   
Hormone receptor status is another important prognostic factor for recurrence as well as 
response to systemic therapy (Kyndi et al., 2008; Panoff et al., 2011; Voduc et al., 
2010)Negative hormone receptor status has been associated with increased risk of LRR in 
women with breast cancer. Specifically, negative estrogen and progesterone receptor 
status were associated with increased risk of LRR in women with breast cancer(Panoff et 
al., 2011).  In the study, Her 2 positive receptor status was associated with a lower LRR 
rate (1.7 in Her2 +, versus 7.5 in Her2  -, P= 0.0032). 
Another retrospective study analyzed the effect of molecular subtypes on recurrence 
among 2, 985 breast cancers in patients who underwent breast conserving surgery with 
radiotherapy, mastectomy alone, and mastectomy with radiation(Voduc et al., 2010).  In 
this study, basal like tumors (ER, PR and Her2 negative tumors) were more likely to have 
local regional recurrence when compared to luminal A tumors (ER or PR positive, Her2 
negative, Ki-67 < 14%)  (Voduc et al., 2010).  
In terms of surgical margins as an important prognostic factor, a study by (Abi-Raad et 
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al., 2011) found that those with positive or close margin status had significantly higher 
risk of LRR when compared with those with negative margins P < 0.0001. 
Therefore, given the availability of more effective chemotherapy/systemic regimens, 
safer methods of delivering PMRT, as well as improved surgical techniques, there is a 
need to further evaluate the actual rates of locoregional and systemic recurrence after 
mastectomy. There is also a need to evaluate the effects of factors such as hormone 
receptor status, nodal status, and margin status on the local and distant recurrence after 
mastectomy in order to identify the subset of patients that could best benefit from PMRT. 
 
Aims and Hypothesis 
• To evaluate the local and distant recurrence rate in women who underwent 
mastectomy for breast cancer. We hypothesize that the rate of local and distant 
recurrence in our patient population will be much lower than that stated in the 
already published large-scale trials. 
• To evaluate the impact of PMRT on local and distant recurrence rates in our 
patient population. Our hypothesis is that patients who received PMRT will have 
a lower rate of local and distant recurrence. 
• To evaluate the impact of hormone receptor status (estrogen, progesterone, 
herceptin) on local and distant recurrence rates in patients who have undergone 
postmastectomy radiation. We hypothesize that patients with estrogen and 
progesterone negative hormone receptor status will have a higher rate of 
recurrence and thus benefit most from PMRT compared to patients with hormone 
receptor positive status. 
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• To evaluate the impact of surgical techniques (margin status, nodes examined) on 
the local and distant recurrence rates. We hypothesize that on average, more 
nodes will be examined in our study group when compared to the Danish and 
British Columbia clinical trials. 
 
Methods  
All breast cancer patients who underwent mastectomy with or without post mastectomy 
radiation at Yale New Haven Hospital between Jan 1, 2000 and December 31, 2004, were 
queried from the hospital cancer registry. Hospital records and pathology records of these 
patients were reviewed via the electronic medical records (EMR). Before review of 
medical records, institutional review board approval was obtained. Patients who did not 
meet the study criteria of having their mastectomy done at Yale New Haven Hospital 
during the study period were excluded. Patients with distant metastasis at time of 
mastectomy were also excluded. In patients with bilateral synchronous breast cancer 
where the two breast cancer cases occurred during the study period, the synchronous 
breast cancers were recorded as two separate cases. The following variables were 
extracted from the medical records: age at surgery, race/ethnicity, laterality of breast 
cancer, date of diagnosis, type of surgery, date of surgery, histology, invasive tumor size, 
pathologic tumor size, pathologic nodal status, total number of nodes examined, total 
number of positive nodes, number of sentinel lymph nodes examined, nuclear grade, 
histologic grade( Bloom Richardson Score), ER status, percent ER status, PR status, 
percent PR status, Herceptin status, Herceptin number (immunohistochemisty), FISH (for 
those that had it tested), surgical margin and radiation therapy, date last seen, status at 
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date last seen and type of recurrence. We consulted the hospital tumor registry database 
to obtain the following variables: radiation therapy, date last seen, recurrence status, date 
of local recurrence and date of distant recurrence. For patients, without adequate variable 
information in the EMR, we consulted the tumor registry to fill in the gaps where 
possible, however, deference was always given to information collected directly from the 
EMR. 
In our study, local recurrence was defined as recurrence to the ipsilateral chest wall and 
axilla. Distant recurrence was defined as recurrence beyond the chest wall and axilla.  
We also collected information regarding use of adjuvant therapy, use of hormonal 
therapy, trastuzamab and other systemic therapy from the EMR when available. 
The student, Oluwatosin Onibokun, worked on the design and planning of the project 
along with Dr Donald Lannin and Dr Meena Moran. The student, Oluwatosin Onibokun, 
examined and extracted all the available data relating to the breast cancer diagnosis, 
treatment and follow-up from the electronic medical records for all the patients who met 
the criteria for inclusion in this study. This included examining pathology reports, 
operative reports and physician notes.  She worked with Dr Lannin and Dr Moran on 
getting data from the hospital tumor registry. She extracted data from the hospital tumor 
registry records. She compared data from the hospital tumor registry with data she 
collected from the EMR and she reconciled the two data using standard guidelines such 
as the American Joint Committee on Cancer (AJCC) tumor staging guidelines, 7th edition 
as well as in consultation with Dr Lannin. She worked jointly with her research advisor 
Dr  Lannin on the computing and statistical analysis of the study data. She also worked 
with Dr Lannin on the interpretation of the study results.   
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Statistical Analysis 
We used the SPSS version 19 to perform statistical analysis.  We used the Chi- square 
method in our bivariate analysis to compare the effect of various factors on recurrence. 
Linear regression using the backward method was used for multivariate analysis.   
 
Results 
Of the 443 patients that met our study criteria, there were 359 (81.1%) cases where the 
local and distant recurrence was known and 84 (18.9%) cases where the local and distant 
recurrence was not known. 
We compared cases where the recurrence outcome was known with those where the 
recurrence was unknown. As seen in table 1, cases with invasive cancers tended to have 
more cases with known recurrence status when compared with cases with non-invasive 
cancers (p= 0.006).  This is likely because patients who undergo a mastectomy for DCIS 
are usually not given any other local or systemic treatment, so they tend to be followed 
by their home town primary care physician rather than returning to the cancer center. 
There was no difference between cases with known and unknown recurrence based on 
age, race, nodal status or receipt of post-mastectomy radiation. Patients were followed for 
a mean of 79.7 months( min: 0.2, max: 138, std deviation: 29.9). We focused our analysis 
on 359 cases where the local and distant recurrence status was known.  
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Table 1: Comparison of patients with known and unknown recurrence status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Recurrence 
unknown 
Recurrence 
known 
P value 
(Chi 
square) 
Total 84 (100%) 359 (100%)  
Age   0.739 
<50 28 (33.35%) 132 ( 36.7%)  
>50 56 (66.6%) 226 (62.9%)  
Unknown 0 (0%) 1 (0/3%)  
    
Race   0.539 
White 69 (82.14%) 294 (81.8%)  
Black 10 (11.9%) 39 (10.9%)  
Hispanic 1 (1.2%) 10 (2.8%)  
Asian 1 (1.2%) 3 (0.8%)  
Other 1 (1.2%) 5 (1.4%)  
Unknown 2 (2.4%) 8 (2.2%)  
    
T stage   0.03 
Insitu 26 (30.9%) 65 (18.1%)  
1 27 (32.1%) 144 (40.1%)  
2 18 (21.4%) 109 (30.3%)  
3 8 (9.5%) 22 (6.1%)  
4 2 (2.4%) 16 (4.4%)  
Unknown 3 (3.6%) 3 (0.8%)  
    
N stage   0.707 
0 40 (47.6%) 213 (59.3%)  
1 17 (20.2%) 75 (20.9%)  
2 5 (5.9%) 25 (7%)  
3 4 (4.75) 11 (3%)  
Unknown 18 (21.4%) 35 (9.7%)  
    
PMRT   0.360 
No 72 (85.7%) 299 (83.2%)  
Yes 8 (9.5%) 48 (13.3%)  
Unknown 4 (4.8%) 12 (3.3%)  
    
Invasiveness    
Non-invasive 26 (31%) 65 (18.1%) 0.006 
Invasive 55 (65.4%) 291 (81%)  
Unknown 3 (3.6%) 3 (0.8%)  
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Table 2: Patient and tumor characteristics for invasive and non-invasive tumors 
 Non-invasive Invasive 
Total 65 (100%) 291 (100%) 
Age   
<50 years old 26 (40%) 106 (36.4%) 
>50 years old 39 (60%) 185 (63.5%) 
Race   
White 54 (83%) 237 (81.4%) 
Black 7(10.7%) 32 (10.9%) 
Asian 0 (0%) 3 (1%) 
Hispanic 2 (3%) 8 (2.7%) 
Other/ Unknown 2(3%) 11 (3.7%) 
Laterality   
Right 21 (32.3%) 133 (45.7%) 
Left 40(61.5%) 140 (48.1%) 
Unknown 4 (6.1%) 18 (6.1%) 
Tumor Histology   
Infiltrating ductal 0 188 (64.6%) 
Infiltrating lobular 0 37 (12.7%) 
Infiltrating lobular and ductal 0 20 (6.9%) 
Mucinous (Colloid) 0 5 (1.7%) 
Intraductal with focal invasion 0 8 (0.03%) 
Intraductal 61 (93.8%) 0 (0%) 
Other / Unknown 4 (6.1%) 33 (11.3%) 
T stage   
Insitu 65(100%) 0 
1 0 144(49.5%) 
2 0 109(37.5%) 
3 0 22(7.6%) 
4 0 16(5.5%) 
Unknown 0 0 
N stage   
0 49 (75.3%) 163 (56%) 
1 0 (0%) 75 (25.7%) 
2 0 (0%) 25 (8.6%) 
3 0 (0%) 11 (3.7%) 
Unknown 16 (24.6%) 17 (5.8%) 
Grade   
1 7 (10.7%) 41 (14.1%) 
2 24 (36.9%) 102 (35.0% 
3 22 (33.8%) 108 (37.1%) 
Unknown 12 (18.4%) 40 (13.7%) 
ER status   
Negative 6 (9.2%) 55 (18.9%) 
Positive 8 (12.3%) 189 (64.9%) 
Not determined/ Unknown 51 (78.4%) 47 (16.1%) 
PR status   
Negative 6 (9.2%) 81 (27.8%) 
Positive 7 (10.7%) 165 (56.7%) 
Not determined / Unknown 52 (80%) 45 (15.4%) 
HER 2 status   
Negative 1 (1.5%) 178 (61.1%) 
Positive 2( 3.07%) 47 (16.15%) 
Indeterminate 0 (0%) 16 (5.55) 
Not determined / Unknown 62 (95.3%) 50 (17.2%) 
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Patients and tumor characteristics 
Of the 359 cases in which local and distant recurrence rates were known, 65 were non-
invasive breast cancers while 291 were invasive breast cancers. Invasiveness was 
unknown in 3 cases; thus a total of 356 cases were analyzed.  
Table 2 highlights the patient and tumor characteristics of the cases.  As can be seen,  
40% ( 26/65) of the non-invasive cases were below 50 years old ( pre-menopausal) while 
60% (39/65) were above 50 years old (menopausal). Similarly for invasive cancers, 
36.4% (106/291) were below 50 years old while 63.5% (185/291) were above 50 years 
old. Of the invasive cancers, 81.4% occurred among white, 10.9% among black, 2.7% 
among Hispanic and 1% among Asian women. The same trend in racial distribution was 
seen for non-invasive cancer. There was left sided laterality in both invasive and non-
invasive cancer with the highest left to right sided predominance seen in the non-invasive 
cancers (61.5% on the left and 32.3% for non-invasive cancers versus 48.1% on the left 
and 45.7% on the right for invasive cancers). For the invasive cancers, 64.6% were 
infiltrating ductal, 12.7% infiltrating lobular, 6.9% infiltrating ductal and lobular, 7% 
mucinous (colloid), and 0.03% intraductal with focal invasion. Of the invasive cancers, a 
majority, 49.5% were 2cm or less (T1), 37.5% were greater than 2cm but less than or 
equal to 5cm (T2), 7.6% were greater than 5cm (T3) while 5.5% had dermal involvement 
(T4). More than half of the invasive cases were node negative (56%), 25.7% had 1-3 
positive nodes (N1), 8.6% had 4-9 positive nodes (N2) and 3.7% had greater than 9 
positive lymph nodes involved.  
Of the invasive cancers, 14.1% were low grade (grade 1), 35% grade 2 and 37.1% were  
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grade 3. Similarly for the non- invasive cancers, 10.7% were grade 1, 36.9% grade 2 
while 33.8% were grade 3. It was more likely that grade was unknown in the non-
invasive cancers when compared to invasive cancers (18.4% versus 13.7% respectively).  
 Most of the invasive cancers were ER positive 189 (64.9%), 55(18.9%) were known to 
be ER negative while ER receptor status was unknown or undetermined in 47 cases 
(16.1%).  The ER status was not determined for most of the non-invasive cancers 
(78.4%). 
In the invasive cancers, HER 2 status was negative in 178 (61%), positive in 47 (16%) 
and indeterminate in 16 (5.5%). HER 2 was deemed indeterminate when the 
Immunohistochemistry (IHC) result was 2+ but the FISH was not determined. The HER 
2 status was not determined in most of the non-invasive cases, as expected. In terms of 
molecular type for invasive cancers, 139 (47.8%) were either ER or PR positive, and 
HER 2 negative (Luminal A); 32(11%) were either ER or PR positive and HER 2 
positive (Luminal HER 2+); 13(4.4%) were ER and PR negative and HER 2 positive, and 
32(11%) were ER and PR negative and HER 2 negative ( triple negative, basal like).  
 
Overall treatment characteristics  
As can be seen in table 3, 151 (51.9%) cases underwent modified radical mastectomy, 82 
(28.2%) cases underwent total mastectomy with negative sentinel lymph node biopsy and 
45 (15.4%) cases underwent total mastectomy.   
An average of 8.96 nodes were examined for the invasive cancers alone (std deviation 7). 
Almost all the non-invasive cases, 63 (96.9%) did not receive post mastectomy radiation, 
while status of PMRT was unknown in 2 cases. Of the invasive cases, 234 (80.4%) of 
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cases did not receive PMRT, 47 (16.2%) received PMRT while status of PMRT was 
unknown in 10 (3.4%) of cases. Surgical margins were close (2mm or less) in 24 (82%) 
of invasive cases.  
Our study showed that higher risk patients tended to get PMRT. As seen in table 4, a 
higher percentage of patients under 50 years old received PMRT when compared to those 
over 50 years of age (16.9% versus 10.7% respectively, P= 0.007).  None of the patients 
with breast carcinoma in situ received PMRT. For the invasive cases, a higher percentage 
of tumors with larger sizes received PMRT when compared to those with smaller sizes 
(4.8%, 22.8%, 40%, 46.7% for T1, T2, T3 and T4 tumors respectively, P<0.001). 
Finally, this same trend was seen by N stage. Those with more positive nodes were more 
likely to receive PMRT when compared to those with fewer positive nodes (2.8%, 25.3%, 
44.8%, 69.3% for N0, N1, N2 and N3 respectively P< 0.001).  
There was very limited information on adjuvant chemotherapy in the EMR. Out of the 
291 invasive cases, 21 were known to have not received adjuvant chemotherapy, 89 were  
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Table 3: Treatment characteristics for invasive and non-invasive tumors  
 
 Non-invasive Invasive 
Surgery   
Modified radical mastectomy 6 (9.2%) 151 (51.9%) 
Total mastectomy  (with negative SLNB) 27 (41.55) 82 (28.2%) 
Total mastectomy 29 (44.6%) 45 (15.4%) 
Other 1 (1.5%) 2 (0.7%) 
Unknown 2 (3.1%) 11 (3.7%) 
   
Nodes Examined   
8 or less nodes 38 (58.4%) 135 (46.4%) 
> 8 nodes 3 (4.6%) 131 (45%) 
No nodes examined 10 (15.35) 6 (2%) 
Unknown 14 (21.5%) 19 (6.5%) 
   
Margin status   
Negative 47 (72.3%) 195 (67%) 
Close( 2mm or < 2mm) 2 (3%) 24 (8.2%) 
Positive 0 (0%) 16 (5.5%) 
Equivocal 0 (0%) 1 (0.3%) 
Unknown 16 (24.6%) 55 (18.9%) 
   
Post-mastectomy radiation   
No 63 (96.9%) 234 (80.4%) 
Yes 0 (0%) 47 (16.2%) 
Unknown 2 (3.1%) 10 (3.4%) 
SLNB= Sentinel lymph node biopsy 
 
known to have received adjuvant chemotherapy, and chemotherapy status was unknown 
in 181 cases. Similarly for hormone therapy, of the 291 invasive cases, 90 were known to 
have received adjuvant hormone therapy, 10 were known to have not received it, while 
adjuvant hormone therapy status was not known in 191 invasive cancer cases. 
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Table 4: Characteristics of patients who received PMRT  
 
 No Yes P value 
Age   0.007 
<50 128(83.1%) 26(16.9%)  
>50 24(89.3%) 29(10.7%)  
unknown 0 1(100%)  
    
T stage   <0.001 
insitu 89( 100%) 0  
1 157(95.2%) 8(4.8%)  
2 95(77.2%) 28(22.8%)  
3 18(60%) 12(40%)  
4 8(53.3%) 7(46.7%)  
    
N stage   <0.001 
0 240(97.2%) 7(2.8%)  
1 65(74.7%) 22(25.3%)  
2 16(55.2%) 13(44.8%)  
3 4(30.8%) 9(69.2%)  
 
 
 
Local and Distant Recurrence Rates. 
 
As can be seen in table 5, a low overall rate of both local and distant recurrence was 
found in our study. Local recurrence occurred in 2(3%) of non-invasive cancers and 
5(1.7%) of invasive cancers. Distant recurrence did not occur in any of the   non-invasive 
cancers, while 32 (11%) of the invasive cancers had distant recurrence. 
 
 
Table 5: Overall local and distant recurrence  
 
 
 Local recurrence Distant recurrence 
 Non-invasive Invasive Non-invasive Invasive 
No 63 (96.9%) 286 (98.2%) 65 (100%) 259 (89%) 
Yes 2 (3%) 5 (1.7%) 0 (0%) 32 (11%) 
Total 65 (100%) 291 (100%) 65 291 (100%) 
 
 
 
 
 	  
15	  
 
 
Prognostic factors for recurrence for invasive cancers 
 
The relationship of a number of tumor and biological characteristics to local recurrence is 
shown in Table 6.  None of these factors were statistically significant, probably because 
of the low incidence of local recurrence, and because a large percentage of the high-risk 
patients received radiation therapy.  On bivariate analyses of invasive cases using chi-
square, differences in tumor size ( p=0.016), nodal status (p=0.022), ER status (p<0.001), 
PR status (p< 0.001) , and molecular subtype ( p <0.001) , were significantly related to 
distant recurrence ( table 7). Differences in age, grade, and HER 2 status were not 
statistically significant for distant recurrence. However on multivariate analysis using 
linear regression model, only differences in nodal status  ( p=0.02) and ER status 
(p<0.001) remained significant for distant recurrence. 
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Table 6: Local Recurrence in relation to PMRT 
 Invasive cancer Non-invasive cancer 
 PMRT+ PMRT- PMRT- 
T stage    
insitu - - 2/63  (3.2%) 
1 0/7   (0%) 1/134  (0.7%) - 
2 0/25  (0%) 2/80  (2.5%) - 
3 0/9  (0%) 1/13  (7.7%) - 
4 1/6  (17%) 0/7  (0%) - 
    
N stage    
0 1/7  (14%) 2/152  (1.3%) 2/47  (4.3%) 
1 0/20  (0%) 2/53  (3.8%) - 
2 0/12  (0%) 0/12  (0%) - 
3 0/7  (0%) 0/2  (0%) - 
    
Grade    
1 0/3  (0%) 2/37  (5.4%) 0/6  (0%) 
2 0/17 (0%) 2/83  (2.4%) 1/23  (4.3%) 
3 1/22  (4.5%) 0/81  (0%) 1/22  (4.5%) 
    
Surgical Margins    
Negative 1/30  (3.3%) 2/159  (1.3%) 2/45  (4.4%) 
Close 0/7  (0%) 1/16  (6.3%) 0/2  (0%) 
Positive 0/4  (0%) 1/10  (10%) - 
Equivocal - 0/1  (0%) - 
    
    
ER status    
Negative 1/11  (9%) 1/42  (2.3%) 1/6 (16.7%) 
Positive 0/33  (0%) 3/151  (2%) 0/8  (0%) 
Not determined 0/2  (0%) 0/23  (0%) 1/44  (2.2%) 
    
PR status    
Negative 1/14  (7.1%) 1/62  (1.6%) 1/6  (16.7%) 
Positive 0/30  (0%) 3/132  (2.3%) 0/7  (0%) 
Not determined 0/2  (0%)          0/23  (0%) 1/45  (2.2%) 
    
HER 2     
Negative 1/35  (2.8%) 2/35  (5.7%) 0/1  (0%) 
Positive 0/7 (0%) 0/14  (0%) 0/2  (0%) 
Indeterminate 0/2 (0%) 0/18  (0%) 1/48  (2%) 
    
Molecular type    
ER/PR+, Her2 - 0/26  (0%) 2/111  (1.8%) 0/1  (0%) 
ER/ PR+, Her2 + 0/4  (0%) 1/25  (4%) - 
ER/ PR-, Her 2 + 0/2  (0%) 1/9  (11.1%) 0/1 (0%) 
Triple negative  (ER-, PR-, Her2-) 1/8  (12.5%) 0/24  (0%) - 
Indeterminate 0/7  (0%) 0/65  (0%) 2/61  (3.3%) 
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Table 7: Bivariate analysis of factors influencing distant recurrence for invasive cancers 
 Distant recurrence P value  (Chi square) 
Age   
<50 14/106  (13.2%) 0.361 
>50 18/185  (9.7%)  
T stage  0.016 
1 10/144   (6.9%)  
2 13/109   (11.9%)  
3 4/22   (18.2%)  
4 5/16   (31.3%)  
N stage   
0 12/163   (7.4%) 0.022 
1 10/75   (13.3%)  
2 6/25   (24%)  
3 3/11   (27.3%)  
Grade   
1 1/41   (2.4%) 0.109 
2 13/102  (12.7%)  
3 16/108   (14.8%)  
Surgical margin  0.029 
Negative 20/195   (10.3%)  
Close  (< 2mm) 5/24   (20.8%)  
Positive 1/16   (6.3%)  
Misc/Equivocal 1/1   (100%)  
ER status   
Negative 15/55   (27.3%) <0.001 
Positive 15/189   (7.9%)  
Not determined 1/26   (3.8%)  
PR status   
Negative 19/81   (23.5%) <0.001 
Positive 12/165  (7.3%)  
Unknown 1/26   (3.8%)  
HER 2 Neu   
Positive 23/178  (12.9%) 0.733 
Negative 4/47  (8.5%)  
Indeterminate 1/16  (6.3%)  
Molecular type   
ER/PR+, Her2 - 11/139   (7.9%) <0.001 
ER/ PR+, Her2 + 1/32   (3.1%)  
ER/ PR negative, Her 2 + 3/13   (23.1%)  
Triple negative  (ER-, PR-, Her2-) 11/32  (34.4%)  
Unknown 6/75   (8%)  
PMRT   
No 20/234   (8.5%) 0.01 
Yes 10/47   (21.3%)  
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Table 8:Local recurrence for invasive cancer cases in pre-menopausal women who 
did not receive PMRT (comparison with Wallgren et al, 2003). 
 
Premenopausal (<50) 
 Wallgren  
10 year 
Recurrence 
(%) 
Wallgren # 
Yale 
5 year 
recurrence 
(%) 
Yale 
10 year 
recurrence 
(%) 
Yale # P value** 
T1 18 219/1209 0 7 1/45 0.006 
T2 25 373/1510 5 5 1/22 0.03 
T3 31 56/178 17 17 1/5 -- 
T4 -- -- 0 0* 0/3* -- 
       
N0 14 92/641 2 2 1/44 0.02 
N1 20 267/1356 4 12 2/28 0.10 
N2 30 186/628 0 0* 0/3* -- 
N3 38 103/272 -- -- -- -- 
*No 10 year survivors 
** 10 year Yale recurrence vs. 10 year Wallgren recurrence 
 
 
Table 9:Local recurrence for invasive cancer cases in post-menopausal women who 
did not receive PMRT (comparison with Wallgren et al, 2003). 
 
Postmenopausal ( >50) 
 Wallgren 
10 year 
Recurrence 
(%) 
Wallgren # 
Yale 
5 year 
recurrence 
(%) 
Yale 
10 year 
recurrence 
(%) 
Yale # P value** 
T1 16 152/970 0 0 0/77 <0.001 
T2 22 261/1181 0 3 1/56 <0.001 
T3 32 33/104 0 0* 0/7* -- 
T4 -- -- 0 0* 0/4* -- 
       
N0 12 64/551 2 2 1/108 <0.001 
N1 16 159/986 0 0 0/25 0.03 
N2 29 146/498 0 0* 0/9* -- 
N3 35 77/220 0 0* 0/2* -- 
*No 10 year survivors 
** 10 year Yale recurrence vs. 10 year Wallgren recurrence 
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Case Studies of Patients with Local Recurrence 
Given the low rate of local recurrence in our study sample, it was interesting to further 
focus on the 7 patients with local recurrences. 
Case 1 
HB was diagnosed with left breast cancer at the age of 48 years old. 
Initial lumpectomy revealed a 5cm tumor with positive margins. Her definitive 
mastectomy took place 8 months later where she underwent modified radical mastectomy 
with reconstruction for infiltrative ductal and lobular carcinoma.  She had multifocal 
tumor with the size of the largest foci of invasive tumor size of 1.8 x 0.9 cm. The size of 
the other invasive foci was 1.1cm. Her tumor was nuclear grade 3 and histology grade 2, 
ER/PR negative and HER 2 positive. 
Sentinel lymph node biopsy was done with 1 out of 2 nodes positive. 5 extra nodes were 
excised and 0/5 were positive. Tumor margins were negative. Pt declined traditional 
adjuvant chemotherapy in pursuit of alternative therapy. She had 6 weekly doses of 
Herceptin and declined further treatment with Herceptin. She did not receive post 
mastectomy radiation. 
Local recurrence: Her local recurrence was diagnosed on routine follow up as a palpable 
nodule in her axilla 10 months after her mastectomy. Pathology revealed 2/3 axillary 
lymph nodes positive. Recurrence was similar in morphology to primary tumor and was 
ER negative, PR negative and Her 2 positive like the primary tumor. Staging at time of 
recurrence was negative.  
 	  
20	  
 
 
Case 2 
HA is a white woman diagnosed with left breast cancer at the age of 37 years. She 
underwent modified radical mastectomy about one month after diagnosis with 
reconstruction. She had infiltrative ductal carcinoma with the invasive component size of 
1.2 x 0.8cm. Tumor was nuclear grade 2, histologic grade 1, ER positive, PR positive and 
Her 2 negative.  One of 3 sentinel nodes were positive for micrometastasis.   The 
resection margin was close ( 2mm or less).  She had adjuvant chemotherapy with 
Doxorubicin, cyclophosphamide and paclitaxel (ACT) and tamoxifen for 5 years. She 
declined post mastectomy radiation.  
Local recurrence:  She developed a palpable nodule in the left area of her left chest 8 
years and 4 months after her mastectomy. Her recurrence was found to be well 
differentiated infiltrative ductal carcinoma that was ER positive, PR positive and HER 2 
negative, similar to her primary tumor in tumor and biologic characteristics. Staging at 
time of recurrence was negative and she received radiation. 
 
Case 3 
QN is a white woman diagnosed with left breast cancer at the age of 70 years.  She had 
infiltrating ductal carcinoma that was 0.9 cm at biopsy and residual 1.5cm at mastectomy. 
0/1 nodes were positive. Tumor was T2N0 , nuclear and histologic grade 2. Her surgical 
margins were positive. Her tumor was ER positive, PR positive and HER 2 negative. She 
did not have post-mastectomy radiation. There is no information on adjuvant therapy on 
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logician.  
Local recurrence: She had recurrence in nodule in left axilla diagnosed 6 years and 3 
months after mastectomy. Her recurrence was found to be poorly differentiated 
adenocarcinoma that was ER positive, PR positive and HER 2 negative, similar to her 
primary tumor.  
 
Case 4 
RP is an African American woman diagnosed with left breast cancer at the age of 34 
years. Pt had lumpectomy 3 months before mastectomy. Pt had modified radical 
mastectomy with reconstruction. Her tumor was mucinous carcinoma, 2.2cm in size   
Bloom-Richardson grade 1, ER positive and PR positive. HER 2 was negative for 
infiltrative component but positive for intraductal component. None of the 15 nodes 
examined were positive (T2N0). Surgical margins were negative.  There is no 
information on adjuvant systemic therapy on the EMR. She did not have postmastectomy 
radiation. 
 
Local recurrence: She developed local recurrence 8 months after mastectomy. There is 
no additional information on recurrence on the electronic medical records or in the 
hospital tumor registry database. 
 
Case 5 
SG is a Hispanic woman diagnosed with right breast cancer at the age of 52 years when 
she presented with bloody nipple discharge. Her primary tumor was DCIS. She 
 	  
22	  
underwent simple mastectomy with reconstruction for DCIS. The DCIS was grade 3, 2.3 
cm in size, ER negative, PR negative with 0/4 nodes positive (TisN0). There were 
isolated tumor cells present. Surgical margins were negative. Her 2 status of her primary 
tumor was not on record.  She did not receive PMRT.  
Local recurrence: A nodule in her right lower axilla was palpated on routine exam 4 
years and 3 months after mastectomy. Pt had re-excision of right chest wall recurrence 
that showed infiltrating ductal nuclear grade 3, ER/PR/HER 2 negative( triple negative).  
Case 6 
SS is a white woman who underwent mastectomy for ductal carcinoma insitu on ther left 
breast at the age of 53 years. Of note, patient had a history of a T2N1 right breast tumor 
18 years prior for which she underwent mastectomy. Then 13 years prior to her 
mastectomy, she developed an infiltrative ductal carcinoma in a left breast which she 
underwent lumpectomy and chemotherapy with CMF and a 10 year use of tamoxifen.   
At the time of her most recent left sided breast cancer, she underwent simple mastectomy 
with negative SLNB with reconstruction for DCIS. Size of DCIS was 1.6mm and there 
was no residual invasive component at mastectomy. She had 0/1 nodes positive and 
negative surgical margins. Her tumor was nuclear grade 2. ER/PR /HER 2 status 
unknown. Pt did not have PMRT.  
Local recurrence: Pt had a recurrence in left excision scar 2 years and 6 months after 
mastectomy that revealed ductal carcinoma insitu.  
 
Case 7 
RD is a white woman who was diagnosed with inflammatory breast cancer with palpable 
axillary adenopathy at the age of 45.  She was treated with Adriamycin/Taxotere on an 
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every 3-week schedule for 6 cycles.  She then underwent a modified radical mastectomy.  
Tumor pathology showed positive margins. Her tumor was ER positive, PR negative, and 
HER 2 negative and there was no evidence of metastases.  She had adjuvant CMF for 5 
cycles after which she received PMRT.  She was then started on tamoxifen therapy, but 
she was found to have malignant right pleural effusion 9 months after mastectomy. 
 
Local recurrence: Pt was clinically found to have recurrence of inflammatory breast 
cancer 1 year after mastectomy (3 months after distant metastasis was diagnosed) on her 
right chest wall, including nodularity. She received Taxotere and recurrence appeared to 
respond given reduced nodularity on physical examination.   
 
Discussion.  
Our study showed a low rate of local and distant recurrence with only 7 cases of local 
recurrence and 32 cases of distant recurrence.  
As hypothesized, our study showed differences in distant recurrence based on differences 
in ER status, PR status and molecular subtypes and tumor size. As can be seen in table 7,  
distant recurrence was higher among ER negative, PR negative, basal like tumors and 
tumors with higher sizes. This result is consistent with previous studies ((Kyndi et al., 
2008; Voduc et al., 2010).  In a sub-group analysis of the Danish Breast Cancer 
Cooperative Group ( BDCG) protocol 82 b and c trials,  within the sub-group of 996 
patients,  ER negative, PR negative was associated with increased LRR and distant 
metastasis on univariate analysis (Kyndi et al., 2008).  PR status remained significant on 
multivariate analysis for LRR ( P=0.02) while HER 2 negative and PR status remained 
significant on multivariate analysis for distant metastasis. And triple negative tumor was 
associated with increased overall mortality ( p=0.02), LRR( p=0.01)  and distant 
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metastasis (p= 0.02) on univariate analysis  while  overall mortality and LRR but not 
distant metastasis were significant on multivariate analysis. In further sub-group analysis 
of patients who did not receive PMRT in the study by Kyndi et al, increased mortality, 
LRR and distant metastasis was seen in patients with triple negative tumors while in 
those randomized to PMRT (486), triple negative, was associated with increased LRR 
(P=0.004) but not overall mortality (P=0.7) or distant metastasis (p=0.99) . Our study did 
not show any significant effects of tumor size or nodal status on local recurrence. This is 
most likely due to the fact that as seen in our results in table 4, patients with higher T and 
N stages were more likely to get PMRT in the first place.  
Patients who received PMRT were more likely to develop distance recurrence (p=0.01). 
However this is most likely due to the fact that patients who were more likely to receive 
PMRT were those with worse prognostic factors and higher risk for recurrence. This most 
likely explains why PMRT dropped off as a significant factor on multivariate analysis.  
Our recurrence rates were lower than expected when compared with a widely cited study 
that evaluated the risk of loco-regional recurrence among women with breast cancer who 
underwent mastectomy and systemic therapy (if indicated) without radiation therapy 
(Wallgren et al., 2003).  
In the study by Wallgren et al, 5, 352 women treated with modified radical mastectomy 
were enrolled in one of seven international breast cancer study groups.  As can be seen in 
table 8, in the premenopausal patients who did not receive PMRT for invasive cancers, 
18% (219/1209) of T1 tumors had local recurrence with or without distant recurrence at 
10 years when compared to a lower 7 % (1/45) at 10 years in our study. For T2 tumors, 
the local recurrence rate was 5% at 10 years (1/22) lower, when compared to 25% 
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(3733/1510) at 10 years in the Wallgren et al study. For T3 tumors, the 10 year 
recurrence rate was 17% (1/5)  lower when compared to the 31% ( 56/178)  in the 
Wallgren et al study. Similarly when comparing by nodal status, the local recurrence 
rates at 10 years were 2% ( 1/44) and 12% ( 2/28) for N0 and N1 tumors in the Yale 
study, when compared to a much higher 14% ( 92/641) and 20% (267/1356) for N0 and 
N1 tumors respectively in the Wallgren study.  
The same trends were seen in postmenopausal women as can be seen in table 9.  A lower 
10 year local recurrence rate of 3% (1/56) was seen in T2 tumors when compared to 22% 
( 261/1181)  in Wallgren et al.  Similarly, the local recurrence rate at 10 years was 2%     
( 1/108) for N0 tumors and 0% ( 0.25) for N1 tumors, lower than 12% ( 64/551)  and 16 
% ( 159/986) in N0 and N1 tumors respectively in Wallgren et al.   
We must note that there was longer follow up in the study by Wallgren et al (median 
follow up 12 to 11.5 years) compared to an average follow up of just below 7 years in our 
study. There is a possibility that recurrences might occur later down the road among our 
patient population by the 10 year mark. However, most of the local recurrences in the 
study by Wallgren et al occurred within the first 7 years of the study, thus covering the 
time span that we have follow up information on the patients in our study. In a study by 
(Woodward et al., 2010) that examined 295 patients with known local regional recurrence 
to see if they were at increased risk for distant metastasis, it was found that the median 
time for local regional recurrence to be diagnosed was 2.2 years and 2.5 years in patients 
who got post mastectomy radiation and mastectomy alone. Patients in the study by 
Wallgren et al were recruited from older clinical trials as far back as 1978, when older 
chemotherapy regimens were used.  This may account for the higher recurrence rates 
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seen in their study when compared to our study. Lower rates of recurrence have also been 
seen in other retrospective studies performed in recent times (Floyd et al., 2006; S. 
Macdonald et al., 2009; Panoff et al., 2011). A retrospective study showed a lower 10 
year LRR rate of 11% in patients with 1 to 3 positive lymph nodes versus 17% seen in 
women with similar nodal status’s in the Danish 82b trial (MacDonald et al, 2009).  Also, 
a relatively low LRR rate of 7.6% was found in a retrospective study of patients with 
node negative breast tumors 5cm or greater in size, who did not receive radiation after 
mastectomy (Floyd, 2006). The low recurrence rates in more recent studies are probably 
as a result of improvements in treatment such as chemotherapy regimen, surgical 
techniques and use of adjuvant hormone therapy.  Improved surgical techniques could 
result in an increase in the number of axillary lymph nodes examined and could help to 
better classify patients. The average number of nodes excised in the Yale cases with 
invasive cancers alone was 9, compared to an average of 7 lymph nodes in the Danish 
trial, which is thought to be low for level I and II axillary dissection (Lee & Jagsi, 2007).  
Our study found low rates of local recurrence among patients with DCIS alone, 2/65  
(3%) . The low rate of local recurrence with DCIS seen in our study is similar to a 
retrospective study that examined 207 patients who underwent mastectomy for DCIS 
where they found a very low rate of loco-regional recurrence 2(0.9%) after a median 
follow up of 4.6 years.   (Chadha, Portenoy, Boolbol, Gillego, & Harrison, 2012) .The 
effect of post mastectomy radiation on local recurrence in their sample could not be 
analyzed given the low rate of recurrence. 
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Local recurrence: Discussion of Case studies 
Most of the cases of local recurrence were palpable which underscores the importance of 
thorough physical exam during routine follow up visits. In addition, only one of the 
patients received post mastectomy radiation. Most of the patients with local recurrence 
were lower risk patients (except the patient in case 1 with a T 3 tumor and the patient in 
case 7 with inflammatory breast cancer- T4). In addition, the patient in case 6 was 
complicated given that she had previously been diagnosed with infiltrating ductal 
carcinoma for which she underwent lumpectomy several years prior, and she eventually 
underwent mastectomy for non-invasive cancer in the same breast. Apart from the 
exceptional cases stated above, most of the patients with local recurrence would not have 
qualified for PMRT to prevent LRR if PMRT were limited to patients with tumor sizes 
greater than 5cm or more than 3 positive axillary lymph nodes. 
Of note, the patient in case 1 highlights some of the challenges to pathologic tumor 
staging. HB in case one initially had a lumpectomy for a 5cm mass with positive margins 
at an outside hospital.  She had a 1.8cm tumor at mastectomy, making her overall tumor 
size 6.8cm (T3 tumor). However, in a few cases, the size of a tumor at biopsy (especially 
if done at an outside hospital or clinic) is not added to the size of the tumor at 
mastectomy creating an underestimation of the size by the hospital tumor registry.  This 
was partially the case in HB, as her tumor size was staged by the tumor registry as a 
T1N1 tumor (considering the tumor size of 1.8cm at mastectomy) as opposed to a T3 
tumor. Fortunately in this case though, the tumor registry assigned an overall American 
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Joint Committee on Cancer (AJCC) staging guidelines score of 3 to the patient, thus 
taking into account the size of the tumor at outside biopsy. However, the T stage still 
remained inaccurate on their record. Therefore in our study, great effort was made to 
ensure correct estimation of tumor size and nodal staging by taking into account data 
from pathology reports found on the EMR, hospital tumor registry, as well as clinician 
notes that commented on tumor size and other tumor variables.  
Also, the case of HB (case 1) who refused traditional adjuvant therapy is very interesting 
example that sheds light on the issue where some patients choose alternative therapy over 
traditional therapy for their breast cancer which could negatively impact their outcomes. 
Although, not as common in the United States, patronage of alternative medicine over 
traditionally known therapies for breast cancer leading to delayed presentation and 
delayed time to receiving definitive treatment is a big problem in developing countries 
and is quoted as one of the reasons for the high mortality rate from breast cancer, 
especially in sub-Saharan Africa(El Saghir et al., 2011; Ezeome, 2010; 
Sankaranarayanan, 2011; Sankaranarayanan et al., 2010). 
 
 
Limitations of Study 
Our study is limited by the number of patients for whom we have no follow up 
information. There was no information on status of local recurrence and distant 
recurrence in 84/443 (18.9%) cases. However as stated earlier, our comparison between 
the groups with known and unknown recurrence did not show any significant difference 
between the two groups except by degree of invasiveness where cases with unknown 
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recurrence status were proportionately more in the non-invasive cases.  This suggests that 
if anything, we might be overestimating our recurrence rate.  
Our study is limited by need for longer follow-up time, especially to detect distant 
recurrences.  
 Our study attempted to collect chemotherapy and hormonal therapy treatment 
information on patients; however there was limited availability of this information both in 
the electronic medical records as well as in the tumor registry database. 
 
Conclusion 
This study shows lower than expected rates of local and distant recurrence in patients 
who have undergone mastectomy for breast cancer in our Yale New Haven Hospital 
patient population.  This needs to be considered when making decisions regarding post-
mastectomy radiation therapy.  
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